KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to 5.11%.

  • Jazz Pharmaceuticals' EBITDA Margin fell 195600.0% to 5.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.46%, marking a year-over-year decrease of 217000.0%. This contributed to the annual value of 17.61% for FY2024, which is 25200.0% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported EBITDA Margin of 5.11% as of Q3 2025, which was down 195600.0% from 65.64% recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' EBITDA Margin ranged from a high of 26.68% in Q1 2021 and a low of 65.64% during Q2 2025
  • Over the past 5 years, Jazz Pharmaceuticals' median EBITDA Margin value was 9.96% (recorded in 2022), while the average stood at 5.04%.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' EBITDA Margin skyrocketed by 621500bps in 2021, and later tumbled by -851200bps in 2025.
  • Jazz Pharmaceuticals' EBITDA Margin (Quarter) stood at 5.51% in 2021, then crashed by -592bps to 27.09% in 2022, then skyrocketed by 145bps to 12.11% in 2023, then skyrocketed by 45bps to 17.53% in 2024, then crashed by -71bps to 5.11% in 2025.
  • Its last three reported values are 5.11% in Q3 2025, 65.64% for Q2 2025, and 17.53% during Q4 2024.